Gene Induction
The introduction of VEGFR2 fragments into tumors slows their growth
Published in Gene Therapy Weekly, May 13th, 2004
According to a study from the Peoples Republic of China, "the interaction of vascular endothelial cell growth factor (VEGF) and its receptors (Flt-1, Flk-1/KDR) regulates tumor angiogenesis. Therefore, blocking the binding of VEGF and the corresponding receptor has become critical for antitumor angiogenesis biological therapy. Our study extracted sFlk-1 fragment from embryo mouse liver using reverse transcription-polymerase chain reaction (RT-PCR), recombined it to retrovirus vector, and transfected it to tumor cell lines (S180 and B16) by the liposome mediated method, then we observed the biological...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-05-13)
More Articles from Gene Therapy Weekly
- Drug Delivery
Adenoviral vectors rely on compatible materials for transfer effectiveness - Liver Cancer Therapy
Vesicular stomatitis virus infusions staunch hepatocellular carcinoma in rats - Transfection
CXCR4 restricts adenovirus-mediated transgene expression to tumor cells - Viral Vector
Ebola virus glycoproteins guide gene therapies to their destinations - Atherosclerosis
Apolipoprotein A-I gene transfer helps the arteries of apo E-deficient mice - Bacterial Genetics
In vivo expression technology identifies virulence genes in H. pylori - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
